111 related articles for article (PubMed ID: 26062755)
21. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells.
Kao CL; Hsu HS; Chen HW; Cheng TH
Cancer Lett; 2009 Dec; 286(2):250-9. PubMed ID: 19560264
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
24. MDM2, an introduction.
Iwakuma T; Lozano G
Mol Cancer Res; 2003 Dec; 1(14):993-1000. PubMed ID: 14707282
[TBL] [Abstract][Full Text] [Related]
25. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
26. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
[TBL] [Abstract][Full Text] [Related]
27. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
[TBL] [Abstract][Full Text] [Related]
28. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
29. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway.
Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W
J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757
[TBL] [Abstract][Full Text] [Related]
30. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.
Zheng M; Yang J; Xu X; Sebolt JT; Wang S; Sun Y
Anticancer Res; 2010 Sep; 30(9):3321-31. PubMed ID: 20944104
[TBL] [Abstract][Full Text] [Related]
32. Mathematical simulation of p53-Mdm2 protein biological system regulation.
Voropaeva OF; Shokin YI; Nepomnyashchikh LM; Senchukova SR
Bull Exp Biol Med; 2014 Aug; 157(4):535-8. PubMed ID: 25110100
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors of MDM2 and MDMX: a structural perspective.
Riedinger C; McDonnell JM
Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
[TBL] [Abstract][Full Text] [Related]
34. MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53.
Sun W; Tang L
Curr Med Chem; 2016; 23(40):4529-4539. PubMed ID: 27686656
[TBL] [Abstract][Full Text] [Related]
35. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.
Lengner CJ; Steinman HA; Gagnon J; Smith TW; Henderson JE; Kream BE; Stein GS; Lian JB; Jones SN
J Cell Biol; 2006 Mar; 172(6):909-21. PubMed ID: 16533949
[TBL] [Abstract][Full Text] [Related]
36. DNA replication in progenitor cells and epithelial regeneration after lung injury requires the oncoprotein MDM2.
Singh S; Vaughan CA; Rabender C; Mikkelsen R; Deb S; Palit Deb S
JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31527309
[TBL] [Abstract][Full Text] [Related]
37. MDM2- an indispensable player in tumorigenesis.
Zafar A; Khan MJ; Naeem A
Mol Biol Rep; 2023 Aug; 50(8):6871-6883. PubMed ID: 37314603
[TBL] [Abstract][Full Text] [Related]
38. Targeting MDM2 for novel molecular therapy: Beyond oncology.
Wang W; Qin JJ; Rajaei M; Li X; Yu X; Hunt C; Zhang R
Med Res Rev; 2020 May; 40(3):856-880. PubMed ID: 31587329
[TBL] [Abstract][Full Text] [Related]
39. The Enigma of p53.
Lozano G
Cold Spring Harb Symp Quant Biol; 2016; 81():37-40. PubMed ID: 27932563
[TBL] [Abstract][Full Text] [Related]
40. Double-edged sword: a p53 regulator mediates both harmful and beneficial effects in experimental acute kidney injury.
McNicholas BA; Griffin MD
Kidney Int; 2012 Jun; 81(12):1161-4. PubMed ID: 22648356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
